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Abstract
The emergence of metallo-b-lactamase (MBL)-producing Enterobacteriaceae is a serious public health concern. Producers have been
repeatedly isolated from patients and long-term care facility (LTCF) residents around Bolzano, and we sought to assess their prevalence
and clinical impact. All routine Enterobacteriaceae isolates from a Bolzano tertiary-care hospital and associated long-term care facilities
in 2008 (n = 5500) were screened for MBLs, with case details reviewed for the source patients. In total, 36 producers were obtained
from 29 patients, comprising 14 Escherichia coli, six Klebsiella pneumoniae, four Klebsiella oxytoca, four Citrobacter freundii, two Enterobacter
cloacae and two Morganella morganii, as well as single Citrobacter amalonaticus, Enterobacter aerogenes, Providencia stuartii and Proteus
mirabilis isolates. All were PCR-positive for blaVIM and 25 were PCR-positive for qnrS; 19 non-K. pneumoniae had blaSHV and one had
blaCTX-M-group1; 13 were from 12 LTCF residents and 23 were from 17 acute-care patients. All these patients had serious underlying
diseases with prolonged hospitalization or LTCF stay; only seven had infections due to the MBL producers, comprising four urinary
tract infections, two catheter-related bloodstream infections and one patient with both a surgical site infection and pneumonia. Five
patients had more than one MBL-producing organism. Pulsed-ﬁeld gel electrophoresis identiﬁed a cluster of six related E. coli, whereas
pairs of K. pneumoniae and C. freundii isolates had >85% proﬁle similarity. Transformants prepared from two isolates were shown to be
PCR-positive for blaVIM, qnrS and blaSHV; their plasmids gave similar restriction fragment length polymorphism patterns, and blaVIM-1,
qnrS1 and blaSHV-12 were detected by sequencing.
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Introduction
The repeated isolation of metallo-b-lactamase (MBL)-prod-
ucing Enterobacteriaceae from sites of infection and the
gut ﬂora of long-term care facility (LTCF) residents in Bolzano
is a major concern [1,2]. MBLs hydrolyse carbapenems and
virtually all b-lactams except aztreonam, to which many
producers are resistant for other reasons. IMP and VIM are
the main transferable MBL types in Europe [3], with VIM MBLs
frequent among Klebsiella pneumoniae in Greece [4]. The
MBLs so far characterized from Enterobacteriaceae in Bolzano
likewise have all proved to be VIM types, as have those from
elsewhere in Italy [5–11]. This repeated detection led us to
study their distribution in Bolzano more comprehensively
by examining the microbiological and epidemiological features
of all the MBL-producing isolates recovered from routine
samples in 2008 in relation to the clinical details of the patients
affected.
Materials and Methods
Screening for MBL-producing Enterobacteriaceae
All Enterobacteriaceae isolates from inpatient and outpatient
specimens at the regional microbiology laboratory in Bolzano
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in 2008 were screened with the Vitek 2 system and the
AST-GN015 card (bioMe´rieux, Marcy l’Etoile, France), which
includes a speciﬁc ESBL-conﬁrmation test. The laboratory
serves an 850-bed hospital, associated LTCFs and a local
population of 200 000. Modiﬁed Hodge tests with imipenem
(10 lg) discs and Escherichia coli ATCC 25922 as the indica-
tor strain [12] and MBL Etests (AB Biodisk, Solna, Sweden)
were performed on: (i) all isolates (except Proteeae) with
imipenem MICs ‡2 mg/L; (ii) on Proteeae with imipenem
MICs ‡8 mg/L; and on (iii) all isolates, irrespective of species,
with cefotaxime, ceftazidime or cefepime MICs ‡2 mg/L and
a negative ESBL test.
Carbapenemase-producing isolates with aztreonam MICs
‡2 mg/L were subjected to ESBL detection tests with amoxi-
cillin/clavulanic acid (20 lg/10 lg) and aztreonam (30 lg)
discs, 15 and 20 mm apart. MICs for MBL producers were
conﬁrmed by British Society for Antimicrobial Chemotherapy
agar dilution methodology [13].
Medical records for all patients with MBL-producing
Enterobacteriaceae were reviewed retrospectively by an
infectious diseases specialist. The data collected included age,
sex, department and reason for hospitalization, hospitaliza-
tions and antibiotic treatments during the preceding
6 months, comorbidities, source and date of isolation of the
carbapenemase producer, infected or colonized status [14],
treatment outcome on day 7, and overall outcome at
6 months.
Molecular methods
Isolates were typed by pulsed-ﬁeld gel electrophoresis
(PFGE) of XbaI-digested genomic DNA [15], with banding
patterns analyzed using BioNumerics software (Applied
Maths, Sint-Martens-Latem, Belgium). They were considered
to be related if there was ‡85% proﬁle similarity [16]. Previ-
ous routine [1] and active-surveillance [2] isolates served as
comparators.
Multiplex PCR for blaCTX-M was performed with published
primers [17]. Isolates with MBL phenotypes were tested by
PCR with consensus primers for blaVIM-1/2 [18] and blaVIM-1
[19]. Published primers were used to seek qnrS [20] and
blaSHV [21].
Sequencing of blaVIM and qnrS PCR products was per-
formed with the same primers as used for ampliﬁcation. To
sequence blaSHV, primers SHV-c, ATGCGTTATATTCGCC-
TGTG, and SHV-d, CTTAGCGTTGCCAGTGCTCG, were
used together with those previously described [21]. In all
cases, products were ﬁrst puriﬁed with the Geneclean Turbo
for PCR Kit (Q-BIOgene, Cambridge, UK) with subsequent
sequencing by the GenomeLab Dye terminator Cycle
Sequencing system, using the Quick Start Kit (Beckman
Coulter, High Wycombe, UK) and a Beckman Coulter CEQ
8000 Genetic Analysis System.
Mega-X E. coli DH10B T1 electrocompetent cells (Invitro-
gen, Paisley, UK) were transformed by electroporation, using
a Bio-Rad Gene-Pulser II (Bio-Rad, Hercules, CA, USA) at
2.0 kV, 200 W and 25 lF, with plasmids extracted by the
method of Kado and Liu [22] and precipitated twice with
ethanol. Transformants were selected on LB agar containing
2 mg/L cefotaxime. Plasmids for characterization were
extracted from these transformants and digested with HpaI
(Promega, Southampton, UK) and BamHI/SacI (Roche, Mann-
heim, Germany). The resulting fragments were separated by
electrophoresis on 0.7% agarose, with pKPN25 [1] and
pKOX105.1 [2] from E. coli DH10B transformants as controls.
Plasmid typing was by PCR (inc/rep PCR) for the major
incompatibility groups [23]. Phylogenetic groups of E. coli
were determined by PCR [24].
Statistical analysis
Imipenem MICs for isolates from colonized and infected
patients were compared using Fisher’s exact test.
Results
Epidemiology and clinical characterization
In total, 36 Enterobacteriaceae from a total of 5500 (0.65%)
tested had phenotypes suggesting MBL production, although
one E. coli was lost during subculture. These isolates were
from 29 patients (Table 1) and belonged to ten species, com-
prising 14 E. coli, six K. pneumoniae, four Klebsiella oxytoca,
four Citrobacter freundii, two Enterobacter cloacae, two Morga-
nella morganii, one Citrobacter amalonaticus, one Enterobacter
aerogenes and one Providencia stuartii. One MBL-positive Pro-
teus mirabilis isolated in December 2007 was also included.
The proportions of MBL producers among inpatient, LTCF
and other outpatient isolates were 23/2300, 13/300 and
0/2400, respectively, with 0/500 among isolates from various
small private clinics and other sources.
Demographic and clinical data for the 29 affected patients
are shown in Table 1; 13 isolates were from 12 LTCF resi-
dents and 23 from 17 patients in acute-care hospital depart-
ments. All the patients had serious underlying diseases with
prolonged hospitalization or LTCF stay; only seven had clini-
cal symptoms signifying infection by the MBL-producing iso-
lates: four had urinary tract infections (UTIs), two had
catheter-related bloodstream infections and one had both a
surgical-site infection and pneumonia; the remaining 22 were
considered to be colonized. Multiple MBL-producing species
were obtained from ﬁve patients (Table 1). One haemodialy-
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sis patient, with C. freundii 430 in 2008, had repeatedly
yielded MBL-producing C. freundii from urine since 2006; sim-
ilarly, the paediatric patient with urinary isolates E. coli 450,
K. pneumoniae 451 and M. morganii 520 had previously
yielded MBL-producing urinary E. coli, K. oxytoca and C.
freundii in 2005 and 2006 [1]. Only four patients had been
administered carbapenems in the 6 months before the isola-
tion of MBL-producing Enterobacteriaceae.
Trimethoprim plus sulphamethoxazole treatment was suc-
cessful in the patients with UTIs due to E. coli 464 and 518,
both of which were susceptible in vitro. Success was achieved
with various antibiotic combinations (Table 1) in the two
patients with catheter-associated bloodstream infections: one
had K. pneumoniae 457, C. amalonaticus 462 and C. freundii
474, whereas the other had E. aerogenes 481. The patient
with surgical-site infection caused by E. cloacae 406 and
pneumonia due to K. oxytoca 424 died of underlying disease,
although combination therapy appeared initially to be suc-
cessful. Outcome data were unavailable for the UTI patients
with E. coli isolates 402 and 480.
PFGE of the MBL-producing isolates
PFGE (Fig. 1) identiﬁed a cluster of six MBL-producing E. coli
isolates with ‡85% proﬁle similarity. These were from three
residents of a single LTCF (isolates 402, 428 and 490), one
orthopaedic unit patient (isolate 476) and two internal medi-
cine ward patients (isolates 515 and 518). Another E. coli iso-
late (no. 520), from a paediatrics patient, had >85% similarity
to a staff-carriage isolate in a previous LTCF surveillance [2].
The cluster of six E. coli isolates all belonged to phylogenetic
group B2 as did another three E. coli isolates, whereas the
other ﬁve MBL-positive E. coli isolates belonged to other
groups. Two K. pneumoniae isolates from nephrology and
orthopaedic unit patients (isolates 491 and 497) had >90%
similarity in PFGE patterns, whereas two of the ﬁve C. freun-
dii isolates (nos. 429 and 430 from internal medicine and
nephrology unit patients, respectively) were >85% similar.
There was no clustering among the E. cloacae or the M. mor-
ganii isolates. Single E. coli (isolate 480) and K. oxytoca (isolate
512) were nontypeable by PFGE.
MICs for MBL-producing isolates
The MIC ranges of imipenem (2 to >128 mg/L), meropenem
(£0.06 to >32 mg/L) and ertapenem (£0.12 to >16 mg/L)
were very wide for the MBL producers, with most values
below the current CLSI susceptibility breakpoint, or in the
intermediate range (Table 2). EDTA decreased imipenem
MICs by at least four-fold for all except the single P. stuartii
isolate and, for 30/35 isolates, this reduction was eight-fold
or greater. Imipenem MICs were >8 mg/L for ﬁve of ten iso-T
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lates from patients with infection vs. 5/25 from colonized
patients (p 0.11).
The MIC distribution of aztreonam was strongly bimodal,
with nine values £1 mg/L and 23 at ‡64 mg/L: 22 of the lat-
ter 23 were ESBL producers with synergy between aztreo-
nam and amoxicillin/clavulanic acid; the remaining one,
E. cloacae 406, lacked blaSHV and blaCTX-M and had a pheno-
type implying derepressed AmpC.
Seventeen MBL-producing isolates were highly resistant to
ciproﬂoxacin, with MICs ‡8 mg/L, whereas MICs for six
were £0.5 mg/L. Aminoglycoside MICs were widely scat-
tered, with more isolates resistant to tobramycin than to
amikacin or gentamicin. Most isolates were resistant to
minocycline but 28/35 were susceptible to tigecycline at the
EUCAST breakpoint of 1 mg/L, with six of the remaining
seven inhibited at 2 mg/L. With the exception of E. aerogenes
481 (MIC, 4 mg/L) and inherently-resistant Proteeae, all the
isolates were susceptible to colistin, with MICs £2 mg/L
(Table 2).
Construction of transformants
C. amalonaticus 462 and C. freundii 474 were selected as
donors for transformation. Both were from the vaginal
secretions of a haematology patient, were PCR-positive for
blaVIM-1, qnrS and blaSHV and had ESBLs (Table 2). Approxi-
mately 10 000 colonies were obtained in each transforma-
tion and three representatives from each were analyzed.
Plasmids from C. amalonaticus 462 and C. freundii 474 were
designated pCAM462.1 and pCFR474.1 and were PCR-posi-
tive for blaVIM-1, qnrS and blaSHV. A second transformant of
C. freundii 474 acquired a plasmid, designated pCFR474.3,
PCR-positive for blaVIM-1 but negative for qnrS and blaSHV, as
also seen for a plasmid from an active-surveillance LTCF
K. oxytoca isolate [2].
10
0
90807060
9080706050
10
0
NT: not typeable with the PCR method 
  E.coli type 
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E. coli 165
E. coli 95
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E. coli
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FIG. 1. Dendrograms illustrating the
relatedness of the blaVIM-positive Entero-
bacteriaceae; the phylogenetic types for
the E. coli isolates are also shown. Long-
term care facility surveillance culture
isolates [2] or previously obtained rou-
tine isolates [1] run for comparison are
underlined. The gradation on the scale
represents the degree of similarity.
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Imipenem MICs for the transformants were in the range 2–
16 mg/L compared to 0.5 mg/L for the E. coli DH10B recipient,
and were reduced by at least eight-fold by EDTA; aztreonam
MICs for the recipient and the blaSHV-negative transformant
with pCFR474.3 were £0.125 mg/L, whereas those for the
blaSHV-positive transformants with pCAM462.1 and
pCFR474.1 were >64 and 0.5 mg/L, respectively. Sequencing
showed that the former plasmid encoded SHV-12, whereas
the latter encoded an SHV-12 variant with a single amino acid
substitution (see below). Ciproﬂoxacin MICs for the qnrS-posi-
tive transformants were 0.25 vs. £0.125 mg/L for the recipient
and the qnrS-negative transformant. Gentamicin and amikacin
MICs were not signiﬁcantly changed relative to that for E. coli
DH10B, whereas the MIC of tobramycin increased from 0.5 to
2–8 mg/L.
Plasmid sizes were: pCAM462.1, 55 kb; pCFR474.1, 60 kb;
and pCFR474.3, 30 kb. Restriction fragment length polymor-
phism after digestion with BamHI/SacI yielded two bands for
pCFR474.3 and three bands for the other two plasmids,
whereas digestion with HpaI yielded three bands for
pCFR474.3, seven for pCAM462.1 and eight for pCFR474.1.
Two HpaI digestion-generated bands were common to all
of the plasmids and were present also in blaVIM-encoding plas-
mids of a transformant of an LTCF-active-surveillance K. oxyt-
oca isolate [2] and in a transformed plasmid from a clinical
K. pneumoniae strain isolated in 2005 [1]. All these present
and previous blaVIM plasmids from Bolzano belonged to IncN.
Sequencing of blaSHV, blaVIM and qnrS in transformants
The blaSHV genes from pCAM462.1 and pCFR474.1 were
partially sequenced. The sequence (772 out of 861 nucleo-
tides) in pCAM462.1 corresponded to blaSHV-12, a known
ESBL determinant [25], whereas that of pCFR474.1 (655 nu-
cleotides sequenced) differed by an A ﬁ G transition, lead-
ing to a Ser238Gly substitution. The blaVIM and qnrS genes of
pCFR474.1 were partially sequenced and were identical to
blaVIM-1 and qnrS1.
Discussion
Enterobacteriaceae with VIM MBLs are still rare in Italy, but
producers have been found repeatedly since 2002
[5–7,9,10,26]. Clonal outbreaks involving K. pneumoniae and
E. cloacae with VIM MBLs occurred in Genoa in 2004–5 [8]
and in Rome in 2007–8 [11] whereas, in Bolzano, multiple
species with IncN blaVIM plasmids have been recorded since
2005 [1,2].
The present study found a 0.65% prevalence of MBL pro-
ducers among clinical Enterobacteriaceae in Bolzano. All the
present source patients had spent >72 h in hospital or in an
LTCF before isolation of the producer(s), and all had severe
underlying diseases. Only seven had clinically-deﬁned infec-
tion with their MBL producer(s), sometimes involving multi-
ple species, whereas 22 were colonized.
Whether the small number of serious infections reﬂects
low virulence or epidemiological reasons remains uncertain;
only four source patients had received carbapenems in the
6 months before isolation of an MBL producer.
The treatment of infections due to MBL producers remains
controversial. One Greek study found high 14-day mortality
in bloodstream infections with VIM b-lactamase-positive
K. pneumoniae, associated with ineffective empirical therapy,
although only in cases where the imipenem MIC was >4 mg/L
[27], whereas another found no mortality difference contin-
gent on the imipenem MIC [28]. Imipenem MICs were
>4 mg/L for isolates from seven of ten of the infected
patients in the present study, without attributable mortality,
although (and in contrast to the Greek series) few patients
had life-threatening infections. Thus, both haematology
patients with central-venous catheter-(CVC)-related bacte-
raemias survived despite (in accordance with internal proto-
cols) being empirically administered meropenem plus linezolid
(one patient) or vancomycin (the other). One of these two
patients, an elderly woman with allogeneic bone marrow
transplantation for acute myelogenous leukaemia (AML), was
given tigecycline as targeted therapy, whereas piperacillin/ta-
zobactam plus levoﬂoxacin was administered to the other, a
65-year-old male with AML with E. aerogenes bacteraemia.
Neither patient showed signs and symptoms of severe sepsis,
and CVC removal probably contributed to successful out-
comes. Co-trimoxazole therapy was successful in two
patients with UTIs due to susceptible strains.
Although some clusters were identiﬁed by PFGE (notably
six E. coli with >85% similarity), remarkable diversity was
apparent among the MBL-producing strains, suggesting hori-
zontal gene transfer as the major factor for dissemination of
VIM MBLs. As also found previously in Bolzano [1] and for
K. pneumoniae isolates from Greece [29,30], blaVIM-1 was
located on various IncN plasmids. Coniugative transfer was
not attempted in the present study but was demonstrated
previously for several such plasmids [1].
Eight of the 14 VIM-positive E. coli were from LTCF resi-
dents, as were ﬁve further isolates belonging to different
species. This association led to an active surveillance in the
largest LTCF in Bolzano in October 2008, revealing 6.3% of
residents and one staff member as being colonized by MBL
producers [2].
Twenty-ﬁve of the 36 MBL producers also had ESBLs: one
E. coli isolate had blaCTXM-group-1, whereas the others mostly
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had blaSHV, identiﬁed in the transformant studied in detail
as blaSHV-12. One isolate, C. freundii 474, with aztreonam-
clavulanate synergy and a relatively low (8 mg/L) aztreonam
MIC, yielded an SHV-12 variant with a Ser238Gly substitu-
tion. This may explain reduced aztreonam resistance,
because Ser238 is on a key b-strand of the catalytic site,
where glycine (as in SHV-1) is associated with much weaker
hydrolysis of oxyimino-cephalosporins than serine, as in
SHV-12 [31]. An association between blaVIM and blaSHV-12
[5,7,11] or blaSHV-5 [8] was previously reported for clinical
Enterobacteriaceae from Italy, although the genes were not
on the same plasmid, as in the present study. Of the 36
MBL-producing isolates, 71% had qnrS, one copy of which
was partially sequenced and identiﬁed as qnrS1. In Europe,
qnrS is mainly reported in Salmonella isolates from outside
Italy but was recorded in an E. coli isolate from an Italian
chicken in 2006 [32]. qnrS1 has been repeatedly found
among Enterobacteriaceae in Bolzano, both in those with
VIM MBLs and those lacking MBLs but producing ESBLs
[1,2], whereas a study in Taiwan found a high prevalence
of qnr genes (78.6%) co-existing on plasmids with blaIMP-8
[33]. Such linkages of qnrS1 with MBL and ESBL genes—on
plasmids that have spread among species—present a major
therapeutic and public health threat.
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